NALORPHINE

Nalorphine is an early opioid antagonist with partial agonist activity that can reverse opioidinduced respiratory depression while producing some analgesia and dysphoria. It acts mainly at and receptors. Side effects include agitation, nausea, vomiting, anxiety, blood pressure changes, and acute withdrawal symptoms in opioiddependent individuals, limiting its modern clinical use. Only GMP materials will be supplied, logistics all according to GDP.

SKU: 3e733a69efe1 Category: Tag:

Product Description


Mechanism of Action

NALORPHINE exhibits a multivector biochemical action pattern, influencing enzymatic cascades, receptormediated signalling, intracellular ion behaviour, mitochondrial oxidative dynamics and transcriptional regulatory networks. Its structural characteristics suggest interaction with catalytic residues, allosteric pockets and regulatory scaffolds, enabling modulation of phosphorylation circuits, secondmessenger systems (cAMP, Ca²⁺, IP), ROS generation, membrane polarization and metabolicflux channeling.

Depending on biological context, NALORPHINE may alter mitochondrial membrane potential, redox buffering capacity, calcium sequestration, cytoskeletal integrity, vesicle trafficking efficiency and transcriptionfactor activation, resulting in broad mechanistic adaptability across experimental systems.

Benefits and Advantages

This compound is highly valued in advanced biochemical and pharmacological research frameworks, including:

  • Highresolution receptorligand mapping and affinity prediction
  • Enzymekinetic profiling and catalyticpathway deconstruction
  • Mitochondrialstress testing, ATPflux analysis and ROSequilibrium studies
  • Integrated multiomics research: transcriptomics, metabolomics, proteomics, phosphoproteomics
  • Cytoskeletal modelling involving actin/tubulin regulation
  • Apoptosis, autophagy, necroptosis and ferroptosis signalling investigations
  • Structureactivity relationship (SAR) exploration and molecular optimisation
  • Pharmacodynamic simulations for mechanistic threshold and doseresponse studies

Side Effects and Risks

Possible laboratoryobserved risks include:

  • Redox imbalance with elevated ROS levels
  • Mitochondrial overactivation or respiratorychain suppression
  • Ionchannel dysregulation affecting Na⁺/K⁺/Ca²⁺ flow
  • Crossactivation or inhibition of unintended receptor systems
  • Cytoskeletal destabilisation and impaired membrane integrity
  • Dosedependent cytotoxicity or induction of apoptotic/autophagic pathways
  • Transcriptional instability and activation of inflammatory cascades (NF-κB, JNK, p38)

Strict biosafety handling, controlled dosing and regulated environmental conditions are required for all experimental use. Not intended for human or veterinary application.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C19H21NO3

Molecular Weight

311.4 g/mol

CAS Number

62-67-9

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

ODORLESS; WHITE OR PRACTICALLY WHITE, CRYSTALLINE POWDER; INSOL IN CHLOROFORM & ETHER; SOL IN DIL ALKALI HYDROXIDE /NALORPHINE HYDROCHLORIDE/

Purity

Purity information is available upon request (COA).

Synonym

Nalorphine; N-Allylnormorphine; Nalorfina; Allylnormorphine; 62-67-9

IUPAC/Chemical Name

(4R,4aR,7S,7aR,12bS)-3-prop-2-enyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol

InChl Key

UIQMVEYFGZJHCZ-SSTWWWIQSA-N

InChl Code

InChI=1S/C19H21NO3/c1-2-8-20-9-7-19-12-4-6-15(22)18(19)23-17-14(21)5-3-11(16(17)19)10-13(12)20/h2-6,12-13,15,18,21-22H,1,7-10H2/t12-,13+,15-,18-,19-/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/5284595;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download